## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.89 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Caution: declining volume (33% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($63.91)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Bearish (Bullish: 1, Bearish: 7)

**1. Investor Alert: Deadline Approaching to Join DexCom, Inc. (DXCM) Class Action - Contact Levi & Korsinsky**
- Source: WHNT.com | 20251227T020831 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has announced a securities class action lawsuit against DexCom, Inc. (DXCM) for investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly concealed. Investors who suffered losses on their DexCom investment are encouraged to contact Levi & Korsinsky to explore potential recovery under federal securities laws.

**2. Lost Money on DexCom, Inc. (DXCM)? Join Class Action Before December 26, 2025 - Contact Levi & Korsinsky**
- Source: WJBF | 20251227T000821 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has filed a securities class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who suffered losses. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and exposing users to health risks. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to contact Levi & Korsinsky to inquire about joining the class action before December 26, 2025.

**3. SWS Partners Purchases 19,073 Shares of DexCom, Inc. $DXCM**
- Source: MarketBeat | 20251227T115740 | Bullish | Relevance: 100%
- SWS Partners increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 100.2% in the third quarter, acquiring an additional 19,073 shares to hold a total of 38,102 shares valued at approximately $2.56 million. DexCom recently surpassed Q3 earnings estimates with EPS of $0.61 and revenue of $1.21 billion, leading analysts to project roughly $2.03 EPS for the current year. The stock currently holds a "Moderate Buy" rating with an average price target of $86.61, and institutional ownership remains high at 97.75%.

**4. Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM)**
- Source: WGN-TV | 20251227T090811 | Bearish | Relevance: 100%
- A securities class action lawsuit has been initiated against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made material design changes to its G6 and G7 glucose monitoring products without FDA authorization, rendering them less reliable and posing significant health risks, thus misleading investors. Levi & Korsinsky, LLP is encouraging affected shareholders to learn about their rights to seek recovery.

**5. DXCM DEADLINE - FINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts DexCom, Inc. Investors to Participate in the Class Action Lawsuit**
- Source: FOX 2 | 20251227T030809 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) for alleged securities law violations during the period of January 8, 2024, to September 17, 2025. The lawsuit claims DexCom made misleading statements regarding unauthorized design changes to its G6 and G7 devices, impacting their reliability and posing health risks. Investors who suffered losses are encouraged to participate and request to be appointed as lead plaintiff by December 26, 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Mizuho | $78 | $75 | +4% |
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Mizuho | main | Outperform |
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)
- JPMORGAN CHASE & CO: 3.2% (+101.9%)

### Key Risks

1. Long-term trend broken: trading 8.8% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.89 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (3 raises, avg +9%). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.89 |
| Forward P/E | 27.2 |
| Current P/E | 32.7 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.7% to 1.4% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >4.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 59. Volume at 33% of 20MA suggests lack of conviction. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.39% (CS: 68) | Neutral |
| RSI_14 | 59.2 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.052x | Above |
| vs SMA200 | 0.912x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $67.47
- **Stop Loss:** $63.91 (5.3% risk)
- **Target:** $74.59 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 387
- **Position Value:** $26,110.89
- **Portfolio %:** 26.11%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*